REGULATORY

Discussions Needed for “Biosame” Products: MHLW Official

July 24, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Fresh discussions will be necessary for so-called “biosame” products, which are manufactured under the exact same conditions as those for their originators, Tomonori Nakayama, pharmaceutical management director of the health ministry, told Jiho. Authorized biosimilars (ABs), have two types -…

To read the full story

Chuikyo Might Take Up "Biosames" for Discussion Around Autumn: Ex-Pharmaceutical Management Director
August 28, 2018

REGULATORY

DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…